Table III.
Clinician-reported clinical characteristics at the time of questionnaire completion (N = 11).
| Clinical Characteristics | Value |
|---|---|
| Neuroendocrine tumor has metastasized, no. (%) | |
| Yes | 11 (100) |
| On octreotide treatment, no. (%) | |
| No | 2 (18.2) |
| Yes | 9 (81.8) |
| Number of octreotide injections in past month | |
| Mean (SD) | 0.8 (0.4) |
| Median (range) | 1.0 (0–1) |
| Value of most recent urinary 5-HIAA test (mg/24 h)* | |
| Mean (SD) | 25.4 (26.7) |
| Median (range) | 19.0 (3–68) |
| Carcinoid therapies received because exiting trial, no. (%) | |
| Embolization‡ | 2 (18.2) |
| None | 5 (45.5) |
| Not applicable; participant on long-term extension of LX1606.202 trial | 4 (36.4) |
*
Three participants had missing values. One participant, whose results were reported in alternative units (5280 ng/mL), was not included in the calculation of the mean.
†
The normal range for the urinary 5-HIAA test is 2 to 6 mg/24 h.17
‡
Often performed on liver metastases in the setting of progressive disease.